Erythropoiesis stimulating agents: approaches to modulate activity
Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be r...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704234/ |
| id |
pubmed-3704234 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-37042342013-07-11 Erythropoiesis stimulating agents: approaches to modulate activity Sinclair, Angus M Review Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be required to achieve required hemoglobin levels. Therefore, a need was identified in some anemic patient populations for erythropoiesis stimulating agents with longer half-lives that required less frequent dosing. This need led to the development of second generation molecules which are modified versions of rHuEPO with improved pharma-cokinetic and pharmacodynamic properties such as darbepoetin alfa, a hyperglycosylated analog of rHuEPO, and pegzyrepoetin, a pegylated rHuEPO. Third generation molecules, such as peginesatide, which are peptide mimetics that have no sequence homology to rHuEPO have also recently been developed. The various molecular, pharmacokinetic, and pharmacodynamic properties of these and other erythropoiesis stimulating agents will be discussed in this review. Dove Medical Press 2013 2013-07-03 /pmc/articles/PMC3704234/ /pubmed/23847411 http://dx.doi.org/10.2147/BTT.S45971 Text en © 2013 Sinclair, publisher and licensee Dove Medical Press Ltd This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Sinclair, Angus M |
| spellingShingle |
Sinclair, Angus M Erythropoiesis stimulating agents: approaches to modulate activity |
| author_facet |
Sinclair, Angus M |
| author_sort |
Sinclair, Angus M |
| title |
Erythropoiesis stimulating agents: approaches to modulate activity |
| title_short |
Erythropoiesis stimulating agents: approaches to modulate activity |
| title_full |
Erythropoiesis stimulating agents: approaches to modulate activity |
| title_fullStr |
Erythropoiesis stimulating agents: approaches to modulate activity |
| title_full_unstemmed |
Erythropoiesis stimulating agents: approaches to modulate activity |
| title_sort |
erythropoiesis stimulating agents: approaches to modulate activity |
| description |
Recombinant human erythropoietin (rHuEPO), such as the approved agents epoetin alfa and epoetin beta, has been used successfully for over 20 years to treat anemia in millions of patients. However, due to the relatively short half-life of the molecule (approximately 8 hours), frequent dosing may be required to achieve required hemoglobin levels. Therefore, a need was identified in some anemic patient populations for erythropoiesis stimulating agents with longer half-lives that required less frequent dosing. This need led to the development of second generation molecules which are modified versions of rHuEPO with improved pharma-cokinetic and pharmacodynamic properties such as darbepoetin alfa, a hyperglycosylated analog of rHuEPO, and pegzyrepoetin, a pegylated rHuEPO. Third generation molecules, such as peginesatide, which are peptide mimetics that have no sequence homology to rHuEPO have also recently been developed. The various molecular, pharmacokinetic, and pharmacodynamic properties of these and other erythropoiesis stimulating agents will be discussed in this review. |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3704234/ |
| _version_ |
1611992604324397056 |